


Clinician Perceptions of Olanzapine

Quantitative survey; N=437 clinicians¹

Clinicians rated their perceived efficacy of olanzapine versus other antipsychotics with mean sentiment scores. Each response was valued at -1 for "less effective than olanzapine," 0 for "comparable," and +1 for "more effective." Unsure responses were excluded.¹


Perceived Efficacy by Symptom Domain

Perceived Efficacy vs Other Antipsychotics (Clinicians)¹



Health Care Provider (HCP) Ratings of Product Use When Side Effects Are Not Considered¹

When would you use olanzapine versus another antipsychotic medication for a patient with schizophrenia, not taking adverse events into consideration?




Clinicians reported that they were more likely or as likely to choose olanzapine than other antipsychotics for acute exacerbation (>74%), first-episode schizophrenia (>62%), and suboptimal response to initial treatment (>61%).¹

Clinicians chose olanzapine for first-episode schizophrenia when patients experience significant severe symptoms, agitation/aggression, insomnia, and/or tolerance of metabolic side effects.¹

When transitioning a patient from oral olanzapine to a long-acting injectable (LAI), 43% of clinicians reported LAI olanzapine as their first choice, to keep continuity of molecule.²

HCP Perceptions of Olanzapine Efficacy Compared to Other Antipsychotics³

How would you rate how olanzapine worked to alleviate your/the patient's symptoms compared to other antipsychotic medications you have tried?



References

- Hansen R, et al. Poster presented at: European College of Neuropsychopharmacology (ECNP) Congress, October 11–14, 2025; Amsterdam, The Netherlands.
- Hansen R, et al. Poster presented at: Psych Congress 2025; September 17–21, 2025; San Diego, CA, USA.
- Data on File (Clinical Study Report, Patients and Caregivers). Parsippany, NJ. Teva Neuroscience, Inc.

For educational purposes only. Educational materials were provided as a service by Teva Pharmaceuticals Medical Affairs. Not for redistribution.
© 2026 Teva Neuroscience, Inc. | SDS-US-NP-00096 | 03/26